Amerikanou, C;
Papada, E;
Gioxari, A;
Smyrnioudis, I;
Kleftaki, S-A;
Valsamidou, E;
Bruns, V;
... Kaliora, AC; + view all
(2021)
Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action.
Pharmacological Research
, 171
, Article 105753. 10.1016/j.phrs.2021.105753.
Preview |
Text
Papada_Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action_AAM.pdf - Accepted Version Download (431kB) | Preview |
Abstract
Mastiha is a natural nutritional supplement with known anti-inflammatory properties. Non-alcoholic fatty liver disease (NAFLD) and Inflammatory bowel disease (IBD) are immune mediated inflammatory diseases that share common pathophysiological features. Mastiha has shown beneficial effects in both diseases. MicroRNAs have emerged as key regulators of inflammation and their modulation by phytochemicals have been extensively studied over the last years. Therefore, the aim of this study was to investigate whether a common route exists in the anti-inflammatory activity of Mastiha, specifically through the regulation of miRNA levels. Plasma miR-16, miR-21 and miR-155 were measured by Real-Time PCR before and after two double blinded and placebo-controlled randomized clinical trials with Mastiha. In IBD and particularly in ulcerative colitis patients in relapse, miR-155 increased in the placebo group (p = 0.054) whereas this increase was prevented by Mastiha. The mean changes were different in the two groups even after adjusting for age, sex and BMI (p = 0.024 for IBD and p = 0.042). Although the results were not so prominent in NAFLD, miR-155 displayed a downward trend in the placebo group (p = 0.054) whereas the levels did not changed significantly in the Mastiha group in patients with less advanced fibrosis. Our results propose a regulatory role for Mastiha in circulating levels of miR-155, a critical player in T helper-17 (Th17) differentiation and function.
| Type: | Article |
|---|---|
| Title: | Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.phrs.2021.105753 |
| Publisher version: | https://doi.org/10.1016/j.phrs.2021.105753 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| Keywords: | MiR-155, Immunity, Th17 cells, Mastiha, Non-alcoholic fatty liver disease, Inflammatory bowel diseases, Inflammation |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10134735 |
Archive Staff Only
 |
View Item |
